secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001140361-22-029557
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics Q2 2022 net loss $9.7M; secures $60M credit line; trial enrollment 230 patients randomized
--------------------------------------------------------------------------------

- Net loss applicable to common stockholders of $9.7M ($0.16/shr) vs $8.5M ($0.15/shr) in Q2 2021.
- R&D expenses rose to $8.1M from $6.5M, driven by NAVIGATE trial costs.
- Cash and equivalents $24.2M as of June 30, 2022; $60M line of credit from Richard Uihlein available.
- NAVIGATE trial: 230 patients randomized, 70 in screening; enrollment expected to complete Q4 2022.
- Planning to file IND with FDA for belapectin plus Keytruda in head and neck cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122029557/0001140361-22-029557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122029557/brhc10040754_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-029557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer